Trident Lifeline Limited (TLL.BO)
BSE · INR · Healthcare · Pharmaceutical Retailers
₹434.50 (+4.21%) as of
Key statistics
- Market cap
- 5.21B
- P/E (TTM)
- 24.23
- EPS (TTM)
- 17.93
- Dividend yield
- 0.00%
- 52-week range
- 229.95 – 437.90
- Beta
- -0.32
- Revenue (TTM)
- 1.39B
- Profit margin
- 15.10%
- Volume
- 58.20k
About Trident Lifeline Limited
Trident Lifeline Limited, together with its subsidiaries, manufactures and markets finished doses in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally. It provides various medicinal products, including pharmaceuticals, nutraceuticals, herbals, and injectables in the form of tablets, capsules, dry powders for oral suspension, oral liquids, ointments, liquid ointments, effervescent tablets, sachets, pastes, gels, solutions, suspensions, ice gels, syrups, and creams, as well as toothpaste and mouthwash. The company is also involved in the manufacturing of formulations under proprietary brands; contract manufacturing arrangements; manufacture, trade, and distribution of skin and hair cosmetic products; and medical devices. It has a strategic alliance with National Institutes of Pharmaceutical Education and Research- Ahmedabad (NIPER-A) for the technology transfer of Vorinostat, a medication for Cutaneous T-Cell Lymphoma (CTCL). Trident Lifeline Limited was incorporated in 2014 and is based in Surat, India.
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- Headquarters
- Surat, India
- Employees
- 46
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.